New drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT05636267
Summary
This early-stage study tested the safety and initial effectiveness of two new drugs, AK119 and AK112, given alone or with chemotherapy, for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that had stopped responding to standard targeted therapy. The trial involved 59 adults and aimed to find the right dose and see if the drugs could shrink tumors. The study was terminated early, and results are not yet widely available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, China
Conditions
Explore the condition pages connected to this study.